Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Study Comparing Immuno-Chemotherapy Interval and Consolidation Radiotherapy in Aggressive CD20+ Non-Hodgkin's Lymphoma
2005-005218-19Phase 3Completed
- Sponsor
- German High Grade Non-Hodgkin's Lymphoma group
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by German High Grade Non-Hodgkin's Lymphoma group. Primary endpoint: Time to treatment failure (TTF). Started Jul 2007; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2005-005218-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005218-19.